Systemic hyperthermia in the treatment of HIV-related Kaposi's sarcoma (KS) confers a survival advantage: long-term results of a Phase I study (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Systemic hyperthermia in the treatment of HIV-related Kaposi's sarcoma (KS) confers a survival advantage: long-term results of a Phase I study (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A10 1993. Unique Identifier : AIDSLINE ICDB/93694410
Alonso K; Pontiggia P; de Bartolomei E; Calvi G; Cuppone Curto F; Nardi C; Lab. Atlanta, Clinica 'Citta di Pavia,' Italy

Abstract: Treatment of HIV-related KS with antiretrovirals, interferon-a, and antineoplastics has not affected survival. Immunologic impairment is the critical factor in disease progression. Now, we report long-term results in 29 men, 2 women with profound immunologic impairment and disseminated KS (median duration, 12 mo) and HIV related opportunistic infections who were treated with a single course of hyperthermia (systemic). No antiretrovirals were employed 72 hr prior to treatment nor in follow-up. No antineoplastics nor interferon-a were employed 2 wk prior to treatment nor in follow-up. Other therapy for opportunistic infection was continued. Core temperature was raised to 42 C and held for 1 hr with extracorporeal perfusion at 0.3 L/min and ex vivo blood heating (to 49 C) as the means of temperature control. Two patients died of treatment complications (CNS bleed; cardiac arrhythmia). At 30 days, 20/29 showed CR/PR. At 120 days, 14/29 maintained tumor regression. At 360 days, 4/29 maintained tumor regression (1 CR persisting at 18 mo). At 120 days, 27/29 remained alive (expected, 20). At 360 days, 19/29 remained alive (expected, 11). In all responders, sustained rises in CD4+ counts and falls in surrogate markers of HIV activity were noted. A comparative trial of systemic hyperthermia with and without interferon-a and/or antineoplastics is now underway in HIV-related KS and non-Hodgkin's lymphoma.

Keywords: Acquired Immunodeficiency Syndrome/MORTALITY/*THERAPY Adult Female Follow-Up Studies Human *Hyperthermia, Induced Male Sarcoma, Kaposi's/MORTALITY/*THERAPY Skin Neoplasms/MORTALITY/*THERAPY Survival Rate ABSTRACT CLINICAL TRIAL, PHASE I
931230
M93C0817

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .